Savant Capital LLC Buys New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Savant Capital LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,543 shares of the company’s stock, valued at approximately $2,258,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. Golden State Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Brooklyn Investment Group raised its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 115 shares during the period. Blue Trust Inc. boosted its position in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. R Squared Ltd acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $61,000. Finally, UMB Bank n.a. increased its position in shares of Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NBIX shares. BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Finally, Guggenheim decreased their target price on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research report on Monday. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $166.90.

Neurocrine Biosciences Trading Up 0.3 %

Shares of NBIX stock opened at $117.18 on Thursday. The company has a market cap of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. The firm has a fifty day moving average price of $138.49 and a 200 day moving average price of $131.02. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Insider Activity at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 980 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $118.39, for a total transaction of $116,022.20. Following the transaction, the chief executive officer now owns 137,658 shares of the company’s stock, valued at $16,297,330.62. This trade represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the transaction, the director now owns 517,030 shares in the company, valued at $79,064,227.60. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 226,647 shares of company stock valued at $33,186,271 in the last ninety days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.